INFORMATION DISCLOSURE STATEMENT

Applicant

Fernandez, et al.

App. No

Unknown

Filed

Herewith

For

METHOD FOR THE SYNTHESIS OF

ANTHRACYCLINE-PEPTIDE

CONJUGATES

Examiner

Unknown

Art Unit

Unknown

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is an Information Disclosure Statement by Applicant (PTO/SB/08 equivalent) listing 13 references to be considered by the Examiner. Also enclosed are 12 copies of foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed upon the filing date of this application and no fee is required.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

By:

Che Swyden Chereskin, Ph.D.

Registration No. 41,466

Agent of Record

Customer No. 20,995

(949) 760-0404

10/522565

PTO/SB/08 Equivalent

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Multiple sheets used when necessary)

SHEET 1 OF 1

Application No.

Filing Date

First Named Inventor

Art Unit

Examiner

Attorney Docket No.

Unknown

DECLE100.001APC

			U.S. PATENT	DOCUMENTS	
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Issue Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		4,360,664	11/23/82	Umezawa, et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T¹	
		WO 99/57126	11/11/99	Park, et al.			
		EP 0 295 119	12/14/88	Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai			
		EP 0 039 060	11/04/81	Zaidanhojin Biseibutsu Kagaku Kenkyukai			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	include fighte of the dution (in ord first EET FERO), the of the diffusion appropriate), the of the field first ages in just	
		Hoes, et al. "Synthesis and Biological Evaluation of Immunoconjugates of Adriamycin and a Human IgM Linked by Poly[N ⁵ -(2-hydroxyethyl)-L-Glutamine]," <i>Journal of Controlled Release</i> , Vol. 38, pp. 245-266, 1996.	
		Krüger, et al. "Synthesis and Stability of Four Maleimide Derivatives of the Anticancer Drug Doxorubicin for the Preparation of Chemoimmunoconjugates," Chemical and Pharmaceutical Bulletin Pharmaceutical Society of Japan, Vol. 45, No. 2, pp. 399-401, 1997.	
		Nagy, et al. "Synthesis and Biological Evaluation of Cytotoxic Analogs of Somatostatin Containing Doxorubicin or its Intensely Potent Derivative, 2-pyrrolinodoxorubicin," <i>Proceedings of the National Academy of Sciences of USA</i> , Vol. 95, pp. 1794-1799, February, 1998.	
		Priebe, et al. "Doxorubicin- and Daunorubicin-Glutathione Conjugates, but not Unconjugated Drugs, Competitively Inhibit Leukotriene C4 Transport Mediated by MRP/GS-H Pump," <i>Biochemical and Biophysical Research Communications</i> , Vol. 247, pp. 859-863, 1998.	
		Rho, et al. "Synthesis of New Anthracycline Derivatives Containing Pyruvic, Aspartic, or N-Acetylaspartic Acid Molecule," Synthetic Communications, Vol. 32, No. 13, pp. 1961-1975, 2002.	
		Rho, et al. "Synthesis of New Anthracycline Derivatives Containing Acetylsalicylic or Palmitic Acid Moiety, Bulletin of Korean Chemical Society, Vol. 22, No. 6, pp. 587-592, 2001.	
		Willner, et al. *(6-Maleimidocaproyl)hydrazone of Doxorubicin—A New Derivative for the Preparation of Immunoconjugates of Doxorubicin,* <i>Bioconjugate Chemistry</i> , Vol. 4, pp. 521-527, 1993.	
		Zunino, et al. "Biologic Activity of Daunorubicin Linked to Proteins via the Methylketone Side Chain," <i>Tumori</i> , Vol. 67, pp. 521-524, 1981.	
		International Search Report, completed November 25, 2003 and issued to a related foreign application.	

H:\DOCS\CSC\CSC-8551.DOC 011905

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.